A novel hiPSC-derived system for hematoendothelial and myeloid blood toxicity screens identifies compounds promoting and inhibiting endothelial-to-hematopoietic transition

DOI: 10.1016/j.tiv.2019.104622

Authors: Irina Elcheva; Mechelle Sneed; Scott Frazee; Zhenqiu Liu; Junjia Zhu; Tyler Wood; Sara Hendrickson; Chuck Oehler; Brad Garcia; Vladimir S. Spiegelman

Step 1: iPSC/ESC maintainance

day 0 ~ 1 (duration missing in database; assumed 1 day)

culture “adherent” human PSC in “mTeSR”. For ECM, use “Matrigel” at “N/A” “N/A”.

Ideally, “PSC” should be obtained at the end of culture.

Step 2: endothelial 1

day 1 ~ 7

culture “adherent” human PSC in “Stemline II medium” for “6” days. “PSC” should be “upregulated” for “ETV2”, “upregulated” for “GATA2”. For ECM, use “Matrigel” at “N/A” “N/A”. Medium should contain factors shown in the following table, and should be changed once in “6” days.

Ideally, “EC” should be obtained at the end of culture.